Flere nye behandlingsmuligheder ved hereditært angioødem

Ugeskrift for Laeger

Volumn 174, Issue 34, 2012, Pages 1894-1898

  Åbom, Anne Louise Nørmølle ^a   Palarasah, Yaseelan ^b   Bygum, Anette ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT INHIBITOR; DRUG DERIVATIVE; ECALLANTIDE; ICATIBANT; KALLIKREIN; PEPTIDE; RECOMBINANT PROTEIN; SERPING1 PROTEIN, HUMAN;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; ERYTHEMA; FEMALE; GENETICS; HUMAN; LARYNX EDEMA; METABOLISM; PATHOLOGY;

ADULT; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT INACTIVATING AGENTS; DIAGNOSIS, DIFFERENTIAL; ERYTHEMA; FEMALE; HUMANS; KALLIKREINS; LARYNGEAL EDEMA; PEPTIDES; RECEPTOR, BRADYKININ B2; RECOMBINANT PROTEINS;

EID: 84866437995     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988;6:595-628.
2. Pappalardo E, Cicardi M, Duponchel C et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000;106:1147-54.
3. www.biobase-international.com (1. marts) 2012
4. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009;161:1153-8.
5. Bork K, Meng G, Staubach P et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119:267-74.
6. Roche O, Blanch A, Caballero T et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005b;94:498-503.
7. Davis AE 3rd. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am 2006;26:633-51.
8. Nussberger J, Cugno M, Amstutz C et al. Plasma bradykinin in angio-oedema. Lancet 1998;351:1693-7.
9. Kaplan AP, Ghebrehiwet B. Does C-2 kinin exist? J Allergy Clin Immunol 2005;115:876.
10. Zuraw BL. Hereditary angioedema. N Engl J Med 2008;359:1027-36.
11. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010;126:918-25.
12. Parish LC. Hereditary angioedema: diagnosis and management - a perspective for the dermatologist. J Am Acad Dermatol 2011;65:843-50.
13. Bork K, Siedlecki K, Bosch S et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000;75:349-54.
14. Lumry WR, Castaldo AJ, Vernon MK et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31:407-14.
15. Bygum A, Zachariae H, Dyerberg J et al. Hereditært angioødem. Ugeskr Læger 2004;166:362-6.
16. Bowen T, Cicardi M, Farkas H et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24.
17. Tarzi MD, Hickey A, Förster T et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clin Exp Immunol 2007;149:513-6.
18. Bygum A, Fagerberg CR, Ponard D et al. Mutational spectrum and phenotypes in Danish families with hereditary angioedema because of C1 inhibitor deficiency. Allergy 2010;66:76-84.
19. Suhrs HE, Ibsen H. Forekomst af angioødem ved blokering af renin-angiotensinaldosteron-systemet. Ugeskr Læger 2012;174:724-9.
20. Cicardi M, Zingale LC, Pappalardo E et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003;82:274-81.
21. Bork K, Barnstedt SE, Koch P et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356:213-7.
22. Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104.
23. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009;19:147-51.
24. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41.
25. Craig TJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8.
26. Zuraw BL, Busse PJ, White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22.
27. Zuraw B, Cicardi M, Levy RJ et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126:821-7.
28. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61.
29. Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transf Apher Sci 2003;29:221-7.
30. Gompels MM, Lock RJ, Morgan JE et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002;55:145-7.